Highlights from 2013 ICAAC, IDWeek, and EACS Meetings
- Details
- Category: HIV Treatment
- Published on Tuesday, 28 January 2014 00:00
- Written by HIVandHepatitis.com
Latest Positive Pulse Newsletter
In this overview Paul Sax from Harvard Medical School and Mark Sulkowski from Johns Hopkins discuss selected highlights from this fall's Interscience Conference on Microbial Agents and Chemotherapy (ICAAC), IDWeek, and the European AIDS Conference. The newsletter is available to all for free, with continuing medical education (CME) credit available for physicians and nurses.
ICAAC 2013: Stribild Is Effective and Well-tolerated in Older People with HIV
- Details
- Category: HIV Treatment
- Published on Tuesday, 01 October 2013 00:00
- Written by Liz Highleyman
The Stribild single-tablet regimen matched both Atripla and boosted atazanavir (Reyataz) in efficacy among people age 50 and older, who responded as well as younger patients, researchers reported at the recent 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy in Denver. Related studies showed that Stribild had durable efficacy through 3 years and caused fewer central nervous system (CNS) side effects than Atripla.
ICAAC 2013: Liver Cancer Often Diagnosed Late with Poor Survival in People with HIV
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 01 October 2013 00:00
- Written by Liz Highleyman
Hepatocellular carcinoma (HCC) is frequently diagnosed at an advanced stage in HIV positive people with hepatitis B or C coinfection, contributing to a high mortality rate that has changed little in recent years, according to a report at the recent 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) in Denver.
ICAAC 2013: New Integrase Inhibitor GSK1265744 Safe and Well-tolerated in 8 Studies
- Details
- Category: HIV Treatment
- Published on Tuesday, 01 October 2013 00:00
- Written by Liz Highleyman
The investigational HIV integrase inhibitor GSK1265744 was well tolerated with no notable safety concerns in a meta-analysis of 8 studies testing the drug as either a pill or a long-acting injection, researchers reported at the recent 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) in Denver.
ICAAC 2013: Tenofovir Vaginal Ring Protects Monkeys on Depo-Provera Against HIV-like Virus
- Details
- Category: HIV Prevention
- Published on Tuesday, 24 September 2013 00:00
- Written by Liz Highleyman
An intravaginal ring containing tenofovir protected all but 1 macaque monkey given hormonal contraceptives and repeatedly exposed to a hybrid human/simian virus similar to HIV, according to a late-breaker presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this month in Denver.
Web Design and Development by